AEON Biopharma, Inc. (AEON)
(Delayed Data from AMEX)
$0.96 USD
-0.01 (-1.06%)
Updated Aug 23, 2024 03:59 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
AEON 0.96 -0.01(-1.06%)
Will AEON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AEON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AEON
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
AEON: What are Zacks experts saying now?
Zacks Private Portfolio Services
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
Other News for AEON
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Aeon Biopharma files $200M mixed securities shelf
Aeon Biopharma price target lowered by $1 at H.C. Wainwright, here's why
AEON Biopharma reports Q2 results
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update